Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis

S Kanters, M Vitoria, M Doherty, ME Socias, N Ford… - The lancet HIV, 2016 - thelancet.com
Background New antiretroviral therapy (ART) regimens for HIV could improve clinical
outcomes for patients. To inform global guidelines, we aimed to assess the comparative …

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review …

RK Gupta, A Hill, AW Sawyer, A Cozzi-Lepri… - The Lancet infectious …, 2009 - thelancet.com
Antiretroviral-therapy rollout in resource-poor countries is often associated with limited, if
any, HIV-RNA monitoring. The effect of variable monitoring on the emergence of resistance …

HLA-B* 5701 screening for hypersensitivity to abacavir

S Mallal, E Phillips, G Carosi, JM Molina… - … England Journal of …, 2008 - Mass Medical Soc
Background Hypersensitivity reaction to abacavir is strongly associated with the presence of
the HLA-B* 5701 allele. This study was designed to establish the effectiveness of …

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV

JE Gallant, E DeJesus, JR Arribas… - … England Journal of …, 2006 - Mass Medical Soc
Background Durable suppression of replication of the human immunodeficiency virus (HIV)
depends on the use of potent, well-tolerated antiretroviral regimens to which patients can …

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a …

CJ Cohen, J Andrade-Villanueva, B Clotet, J Fourie… - The Lancet, 2011 - thelancet.com
Background The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine
(TMC278; Tibotec Pharmaceuticals, County Cork, Ireland), had equivalent sustained efficacy …

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial

ES Daar, C Tierney, MA Fischl, PE Sax… - Annals of internal …, 2011 - acpjournals.org
Background: Limited data compare once-daily options for initial therapy for HIV-1. Objective:
To compare time to virologic failure; first grade-3 or-4 sign, symptom, or laboratory …

[HTML][HTML] Abacavir–lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy

PE Sax, C Tierney, AC Collier, MA Fischl… - … England Journal of …, 2009 - Mass Medical Soc
Background The use of fixed-dose combination nucleoside reverse-transcriptase inhibitors
(NRTIs) with a nonnucleoside reverse-transcriptase inhibitor or a ritonavir-boosted protease …

High sensitivity of human leukocyte antigen-b* 5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients

M Saag, R Balu, E Phillips, P Brachman… - Clinical infectious …, 2008 - academic.oup.com
Background. Although the human leukocyte antigen (HLA)–B* 5701 is highly associated
with a hypersensitivity reaction (HSR) to abacavir (ABC), variable sensitivities have been …

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment–naïve populations and associate with reduced treatment efficacy

JA Johnson, JF Li, X Wei, J Lipscomb, D Irlbeck… - PLoS …, 2008 - journals.plos.org
Background Transmitted HIV-1 drug resistance can compromise initial antiretroviral therapy
(ART); therefore, its detection is important for patient management. The absence of drug …

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.

BG Gazzard - HIV medicine, 2008 - search.ebscohost.com
The article presents guidelines from the British HIV Association for the treatment of HIV-1-
infected adults using antiretroviral therapy. It presents data from clinical trials on the …